I-MAB American Depositary Shares - IMAB STOCK NEWS

I-Mab (Nasdaq: IMAB) has been recognized in the "Honored Companies" and "Best CFO" categories by Institutional Investor's 2021 All-Asia Executive Team survey, highlighting its commitment to innovation and financial management. Since its IPO in 2020, I-Mab has achieved key clinical milestones, maintaining over $6 billion in market capitalization. The company’s pipeline includes 16 assets, with 11 in clinical development. Recently, it raised $418 million in one of the largest PIPE financings and has been added to over 50 global indexes, underscoring its strong market presence.

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in the CMBI Healthcare Corporate Day virtual conference scheduled for July 7-9, 2021. Key executives, including Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, will partake in one-on-one and small group meetings with attendees. I-Mab is focused on developing novel immuno-oncology therapeutics and has a robust pipeline of over 15 clinical and pre-clinical candidates. The company is progressing towards becoming a fully integrated global biopharmaceutical firm with substantial R&D and manufacturing capabilities.

I-Mab (NASDAQ: IMAB) has received approval from the China National Medical Products Administration for its IND application to begin a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus. This multi-center study aims to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics. Felzartamab targets dysregulated CD38-positive B cells, addressing a significant unmet need in SLE treatment. I-Mab is also pursuing registration trials for felzartamab in multiple myeloma across Greater China.

I-Mab (Nasdaq: IMAB) announced the appointment of Andrew Zhu, MD, PhD, to its Scientific Advisory Board. Dr. Zhu is a recognized expert in hepatobiliary cancers and has held key positions at Harvard Medical School and Massachusetts General Hospital. His experience is expected to enhance I-Mab's ongoing development of novel immuno-oncology therapies. This strategic move aligns with the company's mission to innovate in drug development and expand its clinical capabilities, potentially bolstering its competitive position in the biopharmaceutical industry.

I-Mab (Nasdaq: IMAB) announced an investor call on June 7, 2021, to discuss in-depth clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ®) for treating advanced cancers. Uliledlimab, a humanized antibody targeting CD73, aims to enhance anti-tumor immune responses and has shown promising preclinical results. The company is transitioning from clinical development to becoming a fully integrated global biopharmaceutical entity with a robust pipeline of over 15 drug candidates.

I-Mab (Nasdaq: IMAB) has announced the election of Dr. Ruyi He and Professor Rong Shao to its board of directors, effective June 1, 2021. Dr. He, a former Chief Scientist at China's NMPA and current Chief Medical Officer at RemeGen Inc, brings extensive experience in drug evaluation and international policy implementation. Professor Shao is a leading expert in drug administration policies, holding roles at China Pharmaceutical University. Their appointments aim to enhance I-Mab’s strategic growth in the biopharmaceutical sector and bolster its transition into a fully integrated global company.

I-Mab (Nasdaq: IMAB) announced its participation in several upcoming healthcare conferences in June 2021. Key events include the Jefferies Healthcare Conference on June 1 and various one-on-one meetings from June 2-4 and June 7-10. Notably, Dr. Joan Huaqiong Shen will present at the Haitong Annual Investor Conference on June 16. The company aims to advance its mission of developing innovative biologics in immuno-oncology, boasting a robust pipeline of over 15 clinical and pre-clinical candidates.

I-Mab announced promising results from a Phase 1 trial of uliledlimab, a novel CD73 antibody, in combination with atezolizumab for advanced cancer patients. The study reported favorable safety and tolerability, with no dose-limiting toxicities. Out of 13 efficacy-evaluable patients, 23% had complete or partial responses, while 46% showed stable disease. The U.S. trial data will be presented at ASCO 2021, where the abstract was selected as one of the Top 12 for poster discussion. I-Mab will host an investor call on June 7, 2021, to discuss the findings.

I-Mab (Nasdaq: IMAB) announced the initiation of a phase 2 combination trial for lemzoparlimab with azacitidine in newly diagnosed Acute Myeloid Leukemia (AML) patients in China. This trial aligns with an accelerated development plan targeting NDA approval for hematologic malignancies. Preliminary results from ongoing U.S. cohort studies in non-Hodgkin lymphoma and advanced solid tumors are expected by early 2022. Lemzoparlimab is a next-gen anti-CD47 monoclonal antibody, designed to improve anti-tumor activity while reducing anemia risk.